---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-248137"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:17:21.968254+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Madrigal posts Q3 2024 Rezdiffra net sales of $62.2M; commercial coverage exceeds 80%

## Summary
- Third-quarter 2024 net sales of Rezdiffra $62.2M; no product revenue in prior year.
- Cash, equivalents, and marketable securities $1.0B at Sep 30, 2024.
- Operating expenses $178.5M vs $98.5M YoY; SG&A $107.6M driven by commercial launch.
- Commercial coverage achieved for >80% of lives; <5% require biopsy for diagnosis.
- Completed enrollment in MAESTRO-NASH OUTCOMES trial for compensated NASH cirrhosis; EMA decision mid-2025.

## SEC filing metadata
- accession: 0001193125-24-248137
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000119312524248137/0001193125-24-248137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000119312524248137/d788088d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-248137
- JSON: https://secwatch.observer/filing/0001193125-24-248137.json
- Plain text: https://secwatch.observer/filing/0001193125-24-248137.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.